Cette page est disponible uniquement en anglais

Deal or Case news
28.10.2025
NautaDutilh assisted ONWARD Medical N.V. with its EUR 50 million accelerated bookbuild offering. This transaction is one of the first to apply the new options introduced by the Listing Act. Instead of using a full prospectus, a short information document was published, facilitating capital raising for listed companies. The offering shows ONWARD’s continued confidence in NautaDutilh, which has supported the company in all its capital raises since its initial public offering (IPO).
It was valuable to be involved in this transaction that advances technology to make a real difference for people with spinal injuries and other movement disabilities. This is exactly the kind of contribution that matters.
Paul van der Bijl, partner Corporate M&A

Technology in rehabilitation

ONWARD Medical is a global leader in neurotechnology, developing therapies to help people with spinal cord injuries and other mobility challenges regain movement, function and independence. A significant part of the proceeds from this offering will be used to further develop the ARC IM System, an investigational device designed to help stabilise blood pressure in people with spinal cord injuries.

The company is listed on Euronext Amsterdam, Brussels and Paris, allowing NautaDutilh to advise on matters of both Dutch and Belgian law. The NautaDutilh team acted alongside Skadden and was led by Paul van der Bijl, and further consisted of Lentle Nijs, Daan Hagelstein and Brian Cuijpers.

Notification de cookies

Cette fonctionnalité utilise des cookies tiers. Modifiez votre cookie préférences pour visualiser ce contenu ou afficher plus d'informations.
Ces cookies assurent le bon fonctionnement du site. Ces cookies ne peuvent pas être désactivés.
Ces cookies peuvent être placés par des tiers, tels que YouTube ou Vimeo.
En désactivant certaines catégories, les fonctionnalités associées au sein du site risquent de ne plus fonctionner correctement. Vous pouvez modifier vos préférences ultérieurement. Voir plus d'informations.